1 / 86

Corso CINBO Recent advances in the medical treatment of melanoma Roma 21/06/2013

Corso CINBO Recent advances in the medical treatment of melanoma Roma 21/06/2013. Pre-clinical and clinical aspects of peptide-based melanoma vaccines Giorgio Parmiani San Raffaele Foundation, Milano . Tumor destruction by the immune system (are T cells the main player?). NK/NKT. TCD8.

dylan
Télécharger la présentation

Corso CINBO Recent advances in the medical treatment of melanoma Roma 21/06/2013

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Corso CINBORecent advances in the medical treatment of melanomaRoma 21/06/2013 Pre-clinical and clinical aspects of peptide-based melanoma vaccines Giorgio Parmiani San Raffaele Foundation, Milano

  2. Tumor destruction by the immune system (are T cells the main player?) NK/NKT TCD8 Monocytes, DC c IL-2, IFN, TNF... B ly TCD4 Tumor-specific antibodies IL-2

  3. The Melanoma-Associated Antigens

  4. Melanoma-associated antigens (MAAs) recognized by T cells. Which is the best MAA or combination of? • Shared/self/differentiation MAAs (e.g. Mart1, tyrosinase) • Shared/self/cancer testis or germinal MAAs (e.g.MAGE, NY-ESO1) • Universal MAAs (survivin, hTERT) • Mutated, unique MAAs

  5. These different MAAs have been used as immunogens in clinical trials. • Which was the outcome in terms of toxicity, immune response and clinical response? • The immunogenicity

  6. 1-2. Shared self MAAs • Normal subjects and cancer patients show some form of tolerance to “self” MAAs(immune ignorance, peripheral or central tolerance, low frequency of T cell precursors, T regs). • Tolerance needs to be broken (spontaneously or not) in order to elicit a T cell immune response against “self” MAAs. • Thus, these MAAs are considered to be “weak antigens” though despite being the first to be molecularly characterized and used in patients

  7. In vivospontaneoustolerance break (immunogenicity) ofshared selfMAAs. 2 examples

  8. StageI-II StageI-II StageI-II StageIII-IV StageIII-IV StageIII-IV Donors Donors Donors Patients Patients Patients FREQUENCY OF ANTI-MAA CD8 T LYMPHOCYTES AND PROGRESSION OF THE DISEASE gp100209-217 Tyrosinase368-377 Melan-A/Mart-126-35 *** *** *** *** ** ** n.s. *** n.s. 3.3 3.3 3.3 2.8 2.8 2.8 2.3 2.3 2.3 1.8 1.8 1.8 1.3 1.3 1.3 0.8 0.8 0.8 0.3 0.3 0.3 0.3 0.3 0.3 0.2 0.2 0.2 0.1 0.1 0.1 0.0 0.0 0.0

  9. CONCLUSIONS • A hierarchy exists in the spontaneous recognition of “self” TAAs. • Recognition of “self” TAAsincreases with the increased tumor burden (e.g. Melan-A/MART1)

  10. Break of tolerance to shared self TAAs by vaccination

  11. Peptide-based vaccines • Advantages: • Sequence and biochemical features are known • Easy to synthesize (large availability) • Allow a specific immune-monitoring of the patient response to vaccine • Allow assessing the expression of targeted TAA in patients’ tumor cells

  12. Peptide-based vaccines (cont.) • Disadvantages: • Easy degradable in absence of adjuvants • Require appropriate HLA allele to be recognized by T cells (patient selection) • Induce T cells that may not recognize tumor cells • Costs (40-160’000€/each)

  13. Results of first generation (1998-2006) of self peptide-based vaccination of metastatic melanoma patients (Phase I/II studies). In a recent study Slingluff et al.(2008) reported 100% immune response and survival benefit in melanoma patients vaccinated with 12 peptides.

  14. Vaccination with MAGE3.A1 peptide Multicentric European Study Ludwig Institute,Brussels; INT and HSR, Milano Adapted from M.Marchand et al., Int.J. Cancer 1999 14

  15. Use of dendritic cells:which progress ? see Ridolfi’s presentation

  16. Disappointment followed by a drop in the interest in new studies • Which are the reasons of such negative clinical results of active immunotherapy of cancer?

  17. Reasons for the limited clinical response

  18. Factors that interfere with the T cell-mediated anti-tumor response Tumor (Immunosubversion) Lack of antigen or down-regulation of HLA Dysfunction of antigen presentation Release of immune-suppressive factors (IL-10, TGFβ, VEGF) Tumour counterattack (Fas/FasL) IDO, SPARC Expression of FoxP3, CTLA4 Tumor ER stress NFAT1, Exosomes Immune system Immune anergy or ignorance Lack of tissue homing molecules; defective adhesion T-cell receptor dysfunction Inactivation of T-cells within the tumor environment (granzyme B) T-regulatory cells MDSC Epithelial/mesenchimal transition Tie+ Monocytes dysfunction

  19. …but, despite this long list of obstacles, under some conditions immune cells can manage to find and sometime destroy cancer cells. • The understanding of the escape mechanism helps to inhibit or down- regulate them in the clinic thus improving efficacy.

  20. Possible examples

  21. Myeloid suppressor cells are increasedin peripheral blood of stage II-III melanoma patients N=30 p<0.01 p<0-01 N=40 % CD14+CD11b+HLA-DR-/lo N=40 STAGE IV STAGE IIB-IIIC HD MELANOMA

  22. Increased frequency of CD4+CD25Foxp3+Treg is a late event in melanoma patients p= 0.0002 n.s. p= 0.002 p=0.04

  23. Monitoring T regs : unpredictable effect of low-dose cyclophosphamide on the frequency of CD4+CD25highFoxp3+ 10 IIB-IIIC HIGH RISK MELANOMA PATIENTS 8 300mg/m2 3-5 days before vaccination 6 % CD4+CD25highFoxP3+ cells (gated on lymphocytes) cyclophosphamide 4 2 0 P1 P4 cyclophosphamide P0 HD VACCINATION ARM

  24. Cyclophosphamide is effective in a different trial with RCC patients (Walter et al., Nature Med 2013)

  25. de010203040020406080100Time (months)Percentage survival3+Cy 1+Cy 0–Cy 0–Cy 1210010203040020406080Percentage survival100Time (months)bc0246810020406080100Time (months)Percentageprogression-free survival+ Multipeptide vaccination In RCC patients

  26. Conclusions Myeloid-derived suppressor cells are increasedin the peripheral blood of stage II-III melanoma patients Increased frequency of CD4+CD25FoxP3+Tregs is a late event in melanoma patients Not clear the effect of low-dose cyclophosphamide on the frequency of CD4+CD25+Foxp3+

  27. Recent progress in cancer vaccines. The Renaissance of cancer immunotherapy : Phase II-III positive randomized trials: • Melanoma (gp100) • B cell lymphoma • Prostate cancer (Sipuleucel, Provenge) • NSCLC (MAGE) • Renal Cell Carcinoma (IMA901)

  28. Phase III study of gp100 peptide vaccine in melanoma • A phase III multi-institutionalrandomized study of immunization with the gp100 (210M) peptide followed by high-dose of IL-2 compared with high dose IL-2 alone in patients with metastatic melanoma. • Schwartzentruber et al. NEJM 2011

  29. Phase III study of gp100 peptide vaccine (cont.) • 21 centers; total of 185 patients • Stage IV or locally advanced stage III, HLA-A*0201 • Therapy. IL-2: 720’000IU/kg/dose+/- Gp100 (210M) peptide+Montanide • Results. High toxicity (IL-2); RR 22.1% vs. 9.7% (P=0.0223); PFS: 2.9 vs. 1.6 mos (P=0.010); Median OS: 17.6 vs. 12.9 mos (P=0.096)

  30. EVIDENCE FOR CLINICAL ACTIVITY OF CANCER VACCINES

  31. Ongoing Phase II trials of active cancer immunotherapy: number of trials by immunotherapy and cancer type

  32. Self peptide-based melanoma vaccines: Conclusions • A phase IIIstudys showed statistically significant benefit for vaccinated patients. • The use of a) multipeptides, b) patients with limited tumor burden, c) a concomitant modulation of immune suppressive cells, d) combination of chemotherapy/anti-angiogenic agents and vaccines are providing new and promising clinical results.

  33. New targets in cancer vaccination • Stroma: a site of complex and often immune inhibitory interactions among tumor cells, infiltrating lymphocytes, macrophage and fibroblast and different soluble factors (e.g. chemokines). • Cancer stem cells

  34. The role of stroma • Stromal cells take up tumor-derived exosomes becoming susceptible (H. Schreiber) or resistant ( G. Parmiani, L. Rivoltini) to CTL. • Endothelial cell antigens (e.g.VEGFR-2; D.Schadendorf). • Fibroblast antigens • Inflammatory/Immune cells (Tcells, DCs, Monocytes, MDSC, mast cells?) • Chemokines (CCL2-5, -19,-21; CxCL9-13; T. F. Gajewski) • Aim: Altering the tumor stroma to the benefit of the host

  35. Cancer stem cells: A new target of immunotherapy? • Objectives: Identification of molecules with immunological relevance expressed by cancer stem cells and validation of their role as target molecules of immunotherapy. • See Ruggero De Maria presentation?

  36. Rationale for a new generation of cancer vaccines • Early disease • Multiple antigens • New TLR targeting adjuvants (CpG, HSPs) • Down-regulation of Tregs and/or Myeloid Derived Suppressor Cells • Immune-monitoring in blood, LNs and tumor tissue. • Assessment of patient polymorphisms and tumor gene signatures • Combination with other therapeutic agents

  37. Combination with other therapeutic agents (e.g. anti-vascular agents)

  38. Targeted delivery of TNF to tumor vasculature by coupling with the NGR-peptide (a ligand of CD13 expressed byangiogenic vessel) TNF NGR-TNF CNGRCG peptide The antitumor activity of NGR-TNF is >10 times greater than that of TNF in several mouse models Curnis et al., Nat. Biotechnol., 2000 Sacchi et al., Clin. Cancer Res. 2006

  39. Combination of vaccine and NGR-TNF in animal models NGR-TNF DC/OVA DC/OVA NGR-TNF % Surviving Animals Day since Tumor Challenge PBS (n=6) vs NGR-TNF (n=5): NS PBS vs DC/OVA (n=5): NS PBS vs DC/OVA+NGR-TNF (n=6): p = 0.0035 NGR-TNF vs DC/OVA: NS NGR-TNF vs DC/OVA+NGR-TNF: p = 0.0061 DCOVA vs DC/OVA-NGR-TNF: NS Calcinotto et al. J Imunology 2012

  40. A pilot phase I and II study of NGR-hTNF in combination with a peptide-based vaccine (MAGE.A3, NA17.A2) for metastatic melanoma (NGR/Vax/01) • PI: Giorgio Parmiani, MD

  41. Inclusion criteria(cont.) • HLA-A*0201- and/or HLA-A1-positive typing on PBMCs. • Melanoma cells expressing the NA17.A2 or MAGE-3.A1 melanoma antigens in HLA-A2 or HLA-A1 patient, respectively,as defined by PCR analysis on frozen or paraffinized tissue.

  42. NGR/Vax/01. Early results in the clinic • Phase I-II of combination of NGR-hTNF and melanoma peptide vaccine • 9 patients enrolled; • No SAE ; grade I-II local erythema, fever, chills . • Ex-vivo immune response to vaccine 6/8; • Clinical response 5 Long Term SD (4, 5, 8, 11, 15+, 16+, 17+, 22+)

  43. Antigens recognized by T cells: • Shared but expressed on tumor cells only • Shared Cancer/Testis expressed by different tumors and by normal testis or placenta • Shared, differentiation proteins expressed also on normal cells • Unique, mutation-derived,expressed only by a single tumor(e.g. CDK4/m, α-actin-m)

  44. Proteins derived from somatically mutated cancer genes give raise to neo-peptide antigens presented by MHC molecules neo- peptide neo- peptide

  45. A reverse immunology approach to go from mutated cancer genes to neo-peptide antigens and specific T cell immunity Massive sequencing of CAN genes -> Somatically mutated TAAs Bioinformatic epitope prediction (peptides) Investigation of autologous T cell responses in vitro/ex vivo Clinical trial vaccination

  46. PREDICTED EPITOPES DERIVED FROM APC MUTATION MISSENSE A3079T (Y->L) BINDING SOME RAPRESENTATIVE HLA-A ALLELES MUTATED SEQ score W.T. SEQ score HLA-A*01 DTPINLSLKY25DTPINYSLKY 25 ELDTPINLSL 14ELDTPINYSL 11 HLA-A*01 11 LDTPINLSLKY 20 LDTPINYSLKY 20 ELDTPINLSLK 14 ELDTPINYSLK 13 HLA-A*0201 ELDTPINLSL 20 ELDTPINYSL 20 NLSLKYSDEQ 12 NYSLKYSDEQ 2 HLA-A*03 NLSLKYSDE 15 NYSLKYSDE 5 TPINLSLKY 13 TPINYSLKY 13 LDTPINLSLK 16 LDTPINYSLK 16 ELDTPINLSL 15 ELDTPINYSL 12 HLA-A*1101 DTPINLSLK 22 DTPINYSLK 22 HLA-A*26 DTPINLSLKY 28 DTPINYSLKY 28 ELDTPINLSL 20 ELDTPINYSL 19 DGELDTPINL 17 DGELDTPINY 19 HLA-A*6801 DTPINLSLK 24DTPINYSLK 20 The maximal score for peptides binding HLA-A*0201 is 36. Influenza A matrix GILGFVFTL scores 30

  47. Vaccination with unique TAAs.A new genomic strategy • Cancer cells contain somatic mutations detectable by new sequencing technology (Sjoblom et al., Science 2006; Parsons et al., Science 2008). These mutations can generate candidate new T cell epitopes. • Breast and colorectal cancers may accumulate 7-10 new HLA-A*0201 epitopes that may define an individual tailored polyvalent vaccine (Segal et al., Cancer Res 2008) • Driver mutations/each melanoma in 120 genes

  48. P. Robbins Trial? • At the moment I am not aware of any ongoing cancer vaccination program based on individually mutated cancer gene-products but I know that several research groups are pursuing this idea.

  49. Acknowledgments • Financial support: • AIRC, Milano • Alleanza contro il Cancro (ACC), Rome • Italian Network for Biotherapy of Tumors (NIBIT), Siena • European Commission (ATTACK) • Collaborators: • Cristina Maccalli, Vincenzo Russo, Paolo Dellabona, Gloria Sovena, (San Raffaele Scientific Institute, Milano) • Licia Rivoltini, Chiara Castelli, Mario Santinami, (National Tumor Institute, Milano)

  50. END OF THE PRESENTATION. • Thank you for your attention!

More Related